Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 1,72€ (+647,83%). La mediana è 1,72€ (+647,83%).
| Acquista |
8 |
| Mantieni |
4 |
| Vendi |
1 |
Notizie Vai al feed delle notizie
Accuray reports mixed Q4 results: revenue weaker, stock under pressure
Accuray slightly beat adjusted loss guidance with EPS of -$0.02 in Q4 but missed revenue estimates with $100.91 million (‑21% year over year). Product revenue plunged 42% in the quarter, while the service business grew 6% and gross margin improved to 34.8%. Management declined to give formal guidance for 2027 due to geopolitical and tariff-related uncertainties, but announced cost cuts, service growth initiatives and a debt-conversion transaction. The stock fell sharply after the results, and the company’s market position remains weighed down by high debt and persistently weak device sales. » Altro su de.investing.com
Accuray withdraws full-year guidance after weak quarter and cites geopolitical turbulence
Accuray reported Q3 revenue of $104.8 million (-7%), missed expectations, and recorded adjusted EBITDA of $3.8 million with a GAAP net loss of $11.8 million. The stock fell in after-hours trading and is trading near its 52-week low. Management cites conflicts in the Middle East, uncertainties in China and tariff debates as reasons and has withdrawn the 2026 full-year guidance. The company meanwhile emphasizes ongoing transformation measures with already realized margin improvements and expects further cost improvements for 2027. » Altro su de.investing.com
Accuray adjusts advisory agreement and cuts cash compensation by 50% to reduce costs
Accuray amended the advisory agreement with Dedication Capital (connected to director Steven F. Mayer): cash fees and minimum premiums for certain periods were reduced by 50%, expected to save at least $362,500. Time-based vesting conditions for 916,336 restricted shares and all performance share awards were deemed satisfied as of April 1; 333,004 remaining shares are scheduled to be issued on October 31, 2026, and the agreement’s termination date was extended to October 31, 2026. The adjustment comes against the backdrop of high debt of $174 million and a market capitalization of $49.75 million; the stock lost 73% in six months but recently gained about 8%. Additionally, Accuray reported Q2 revenue of $102.2 million (below expectations) with EPS of -$0.11, BTIG cut its price target from $4 to $2, and NASDAQ flagged ongoing minimum-price violations. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 88,43M | 18,28% |
| Utile lordo | 31,14M | 5,84% |
| Utile netto | −1,70M | 278,50% |
| EBITDA | 62,21k | 99,07% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 27,74M€ |
Numero di azioni | 118,96M |
Massimo/minimo a 52 settimane | 1,80€ - 0,19€ |
| Dividendi | No |
Beta | 1,39 |
Rapporto P/E | −0,69 |
Rapporto PEG | 0,00 |
Rapporto P/B | 0,80 |
Rapporto P/S | 0,08 |
Profilo aziendale
Accuray Incorporated entwirft, entwickelt, produziert und vertreibt Radiochirurgie- und Strahlentherapiesysteme für die Behandlung von Tumoren in Nord- und Südamerika, Europa, dem Nahen Osten, Indien, Afrika, Japan, China und dem restlichen asiatisch-pazifischen Raum. Das Unternehmen bietet das CyberKnife System an, ein robotergestütztes stereotaktisches Radiochirurgie- und stereotaktisches Strahlentherapiesystem, das für die Behandlung verschiedener Krebsarten und Tumore im Körper eingesetzt wird, z. B. Prostata, Lunge, Gehirn, Wirbelsäule, Leber, Bauchspeicheldrüse und Niere. Das Unternehmen bietet auch das TomoTherapy-System an, einschließlich des Radixact-Systems, das aus einem integrierten Strahlentherapiesystem besteht, das für die Behandlung einer Reihe von Krebsarten entwickelt wurde. Darüber hinaus bietet es Kundendienst, Installation, Schulung und andere professionelle Dienstleistungen nach Vertragsabschluss an. Das Unternehmen vertreibt seine Produkte in erster Linie direkt an Kunden, darunter Krankenhäuser und eigenständige Behandlungseinrichtungen, über seine Vertriebsorganisation sowie an Kunden über Handelsvertreter und Einkaufsgemeinschaften in den Vereinigten Staaten und an Kunden direkt und über Vertriebshändler und Handelsvertreter international. Accuray Incorporated wurde 1990 gegründet und hat seinen Hauptsitz in Sunnyvale, Kalifornien.
| Nome | Accuray |
| CEO | Stephen R. LaNeve |
| Sede centrale | Madison,
wi Stati Uniti |
| Sito web | |
| Settore | Beni voluttuari |
| Industria | Beni durevoli per la casa |
| Quotazione in borsa | 08/02/2007 |
| Dipendenti | 990 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | ARAY |
London Stock Exchange | 0H8I.L |
Frankfurt | XEJ.F |
Düsseldorf | XEJ.DU |
London | 0H8I.L |
SIX | XEJ.SW |
München | XEJ.MU |
Scopri gli asset
Gli azionisti di Accuray investono anche nei seguenti asset
